What is Arbutus Biopharma Operating Cash Flow per Share?
Arbutus Biopharma's operating cash flow per share for the
three
months ended in Mar. 2025 was $-0.07.
Arbutus Biopharma's operating cash flow per share for the trailing twelve months (TTM) ended in Mar. 2025 was $-0.31.
During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 18.10% per year.
During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 20.80% per year.
During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 10.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.
The historical rank and industry rank for Arbutus Biopharma's Operating Cash Flow per Share or its related term are showing as below:
ABUS'
s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -35.3 Med: 10.25 Max: 43.9
Current: 18.1
During the past 13 years, Arbutus Biopharma's highest 3-Year average Operating Cash Flow per Share Growth Rate was 43.90% per year. The lowest was -35.30% per year. And the median was 10.25% per year.
ABUS's 3-Year OCF Growth Rate is ranked better than 60.31% of 1217
companies
in the Biotechnology industry
Industry Median: 9.1
vs ABUS: 18.10
Arbutus Biopharma Operating Cash Flow per Share Historical Data
The historical data trend for Arbutus Biopharma's Operating Cash Flow per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Arbutus Biopharma Operating Cash Flow per Share Chart
Competitive Comparison of Arbutus Biopharma's Operating Cash Flow per Share
For the Biotechnology subindustry, Arbutus Biopharma's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arbutus Biopharma's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arbutus Biopharma's Price-to-Operating-Cash-Flow distribution charts can be found below:
* The bar in red indicates where Arbutus Biopharma's Price-to-Operating-Cash-Flow falls into.
Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.31
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arbutus Biopharma Operating Cash Flow per Share Related Terms
Thank you for viewing the detailed overview of Arbutus Biopharma's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ABUS has been successfully added to your 